For AD, Aꞵ 42/40 ratios and specific p-tau isoforms, such as p-tau181 and p-tau 217, have been useful for diagnosis and have recently shown utility in monitoring and assessing outcomes of amyloid-based clinical trials [48, 96]. The gene discussed is MAPT; the disease is Alzheimer disease.